Houston-based research organization teams up with SpaceX for historic mission

space health

The first crew of all civilians is headed into orbit this month — and they are going to bring back essential research. Photo via inspiration4.com

The world's first all-civilian human spaceflight mission to orbit will be participating in health-related research projects sponsored by a Houston organization.

The crew of Inspiration4 will contribute to research projects that the Translational Research Institute for Space Health, or TRISH, at Baylor College of Medicine will sponsor. The project is a collaboration is between TRISH, SpaceX, and investigators at Weill Cornell Medicine.

"The crew of Inspiration4 is eager to use our mission to help make a better future for those who will launch in the years and decades to come," says Jared Isaacman, commander of the Inspiration4 mission, in a news release. "In all of human history, fewer than 600 humans have reached space. We are proud that our flight will help influence all those who will travel after us and look forward to seeing how this mission will help shape the beginning of a new era for space exploration."

According to the release, all biomedical data collected for the Inspiration4 mission will be accessible through an open data repository funded and overseen by TRISH. The mission will include the following TRISH-sponsored research:

  • Collect research-grade ECG activity, movement, sleep, heart rate and rhythm, blood oxygen saturation, cabin noise and light intensity.
  • Perform a series of tests in the Cognition app designed to assess changes in behavioral and cognitive performance. This is the same app that is currently used by astronauts in NASA-funded research studies.
  • Scan organ systems via a Butterfly IQ+ Ultrasound device, which is designed with artificial intelligence guidance for non-medical experts. Data collected will determine if non-medical experts can self-acquire clinical grade images without guidance from ground support and will provide a timeline of biological changes before and during spaceflight. This device is also currently being tested by astronauts on the International Space Station.
  • Collect and test drops of blood during spaceflight for markers of immune function and inflammation using a state-of-the-art miniaturized device called the Vertical Flow Immunoassay.
  • Use balance and perception tests pre-flight and immediately post-flight to measure sensorimotor adaptation during changes of gravity. These tests are currently performed by astronauts upon return from spaceflight.
  • Archive, fully analyze, and share resulting biomedical samples and data in collaboration with investigators at Weill Cornell Medicine and research data in an open format database to enable greater collaborative research.

Researchers at Weill Cornell Medicine will be collecting the environmental and biomedical data and biological samples from Inspiration4's four crew members before, during, and after the mission. These samples and data will be added to a planned Biobank that will hold cryogenically-frozen samples and data from the Inspiration4 mission. The sample collection will enable long-term research and health monitoring for astronauts. WorldQuant is providing funding support for the work at Weill Cornell Medicine.

The mission, which will be aboard SpaceX's Falcon 9, is slated for September 15 from Launch Complex 39A at NASA's Kennedy Space Center. The three-day mission will target approximately a 575 km orbit, flying farther from Earth than any human spaceflight since the Hubble Space Telescope repair missions. Inspiration4's goal is to inspire humanity and raise money for St. Jude Children's Research Hospital.

The space mission will be riding aboard SpaceX's Falcon 9. Photo via inspiration4.com

From Your Site Articles
Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Houston humanoid robotics startup taps Amazon veteran to lead manufacturing

new hire

Persona AI, a Houston-based startup that’s developing AI-powered humanoid robots for manufacturers and other businesses, has hired Brian Davis as head of global manufacturing.

Davis previously guided teams at Amazon Robotics and Dell Technologies. During his tenure at Amazon Robotics and Dell, both companies saw major increases in manufacturing volumes within a four-year period. Davis oversaw manufacturing, supply chain, logistics, quality assurance and real estate.

“Davis steps into this role [at Persona AI] as industrial enterprises face an urgent and accelerating challenge: a structural shortage of capacity for welding, fabrication, and heavy maintenance in dynamic environments, precisely the high-value, high-risk tasks where humanoid robots can deliver the greatest impact,” according to a company news release.

Davis comes aboard as Persona AI, founded in 2024, seeks to meet demand generated by deals with HD Hyundai and POSCO Group to make humanoids for shipyards and steel plants, and by a pilot program with the State of Louisiana.

“Now is the perfect time to accelerate our production capabilities as we rapidly close the gap between what’s possible in the lab versus what’s driving real commercial value,” Davis says.

“Building industrial-rated humanoid robots and production-deployable AI is only one piece of the puzzle,” he adds. “Producing humanoids at scale will require systematic supply chain management, stringent quality control, and building the playbook for safe, high-volume manufacturing. That’s what I’m here to build.”

Last year, Persona AI raised more than more than $10 million in pre-seed funding. The company also named a new head of commercial strategy in March.

Houston startup’s brain implant for depression advances to clinical trial

moving forward

Houston-based Motif Neurotech has received FDA approval to move forward with its first clinical trial for its innovative way to fight treatment-resistant depression and other mental health disorders.

The company has developed a brain-computer interface technology based on research from Rice University. The blueberry-sized, wirelessly powered implantable device known as the Digitally-programmable Over-brain Therapeutic (DOT) stimulator delivers electrical stimulation to brain circuits linked to depression. The DOT stimulator sits in the skull above the dura without touching the brain and is considered an alternative to transcranial magnetic stimulation, which requires multiple treatment sessions and can cause headaches.

“The goal for this technology is that it would be the mental health equivalent of a continuous glucose monitor for diabetes,” Jacob Robinson, a Rice University professor of electrical computer engineering and bioengineering and CEO of Motif Neurotech, said in a news release. “What has been really special for me personally on this journey is to be able to work all the way from a concept through the process of research and development funded by the federal government at Rice, and take that into a product that is going to affect people’s lives for the better.”

Eligible adults whose depression has not improved after trying multiple therapies can take part in the study. The clinical trial will be conducted in collaboration with Baylor College of Medicine, Brain Health Consultants (Houston), UT Health Houston, Massachusetts General Brigham, Emory Healthcare, University of Iowa, University of Utah Health and New York University, according to Rice.

Motif also announced that it was one of the first teams selected for ARPA-H’s EVIDENT initiative, which recently awarded up to $139.4 million to spur new, effective therapies for behavioral health. Through the initiative, Motif will collect additional data alongside its clinical trial.

“The idea with this funding is to support a number of teams who have rapid-acting interventions for a mental health condition and to collect additional data to help determine with greater precision whether a treatment is working, how it is working and which patients are benefitting most from which course of treatment,” Robinson added in the release.

Motif Neurotech was spun out of Robinson’s and Professor Kaiyuan Yang’s labs at Rice, along with collaborators and co-founders Dr. Sameer Sheth at Baylor College of Medicine and Dr. Sunil Sheth at the University of Texas Health Science Center at Houston. It was founded through the Rice Biotech Launch Pad. The company closed its Series A round with an oversubscribed $18.75 million last year.

New immersive experience Time Mission clocks into Houston this summer

It's Time

Time for a new immersive experience to come to Houston: Time Mission, a kid-friendly, team-based adventure, is scheduled to land at the Marq-E Entertainment District in summer 2026.

Created by LOL Entertainment, a location-based entertainment company specializing in immersive attractions, Time Mission blends physical and mental challenges in a fast-paced experience, a release says. Players take on real-world tasks like cracking codes, dodging lasers, solving riddles, and exploring hidden tunnels to earn points for their team.

Racing through 25-plus unique portals, teams of two to five players embark on a time-travel journey across the past, present, and future, all while collecting points and battling the clock. The website says the attraction is appropriate for "players age 6 to 106."

“We’ve seen a shift in how people seek entertainment, choosing immersive adventures that foster connection and excitement," says Rob Cooper, CEO of LOL Entertainment, in the release. "We’re excited to introduce [Texas] to an experience where strategy, innovation, and teamwork collide."

There are currently Time Mission locations in Pennsylvania, New York, Rhode Island, Virginia, Illinois, and Belgium. Dallas will be the first Texas location, followed by Houston.

Immersive attractions have been popular in Houston for several years, from Meow Wolf just north of downtown to interactive experiences dedicated to balloons and more.

Time Mission will be located in a 10,000-square-foot space at the Marq-E Entertainment District (7620 Katy Fwy., Ste. 355). The exact opening date will be announced at a later time.

---

This article originally appeared on CultureMap.com.

View All Listings